Metformin-induced chemosensitization to cisplatin depends on P53 status and is inhibited by Jarid1b overexpression in non-small cell lung cancer cells

Metformin has been tested as an anti-cancer therapy with potential to improve conventional chemotherapy. However, in some cases, metformin fails to sensitize tumors to chemotherapy. Here we test if the presence of P53 could predict the activity of metformin as an adjuvant for cisplatin-based therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Tortelli, Tharcisio Citrangulo, Tamura, Rodrigo Esaki, de Souza Junqueira, Mara, da Silva Mororó, Janio, Bustos, Silvina Odete, Natalino, Renato Jose Mendonça, Russell, Shonagh, Désaubry, Laurent, Strauss, Bryan Eric, Chammas, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507253/
https://www.ncbi.nlm.nih.gov/pubmed/34528900
http://dx.doi.org/10.18632/aging.203528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507253/
https://www.ncbi.nlm.nih.gov/pubmed/34528900
http://dx.doi.org/10.18632/aging.203528

Ejemplares similares